192 related articles for article (PubMed ID: 33618274)
1. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
3. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Bacteremia Caused by
Drozdinsky G; Neuberger A; Rakedzon S; Nelgas O; Cohen Y; Rudich N; Mushinsky L; Ben-Zvi H; Paul M; Yahav D
Microb Drug Resist; 2021 Mar; 27(3):410-414. PubMed ID: 32808858
[No Abstract] [Full Text] [Related]
5. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
[TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.
Petersen MW; Perner A; Sjövall F; Jonsson AB; Steensen M; Andersen JS; Achiam MP; Frimodt-Møller N; Møller MH
Acta Anaesthesiol Scand; 2019 Aug; 63(7):973-978. PubMed ID: 31020663
[TBL] [Abstract][Full Text] [Related]
8. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
10. Empirical carbapenems or piperacillin/tazobactam for infections in intensive care: An international retrospective cohort study.
Meier N; Munch MW; Granholm A; Perner A; Hertz FB; Venkatesh B; Hammond NE; Li Q; De Bus L; De Waele J; Kauzonas E; Sjövall F; Møller MH; Helleberg M
Acta Anaesthesiol Scand; 2024 Jul; 68(6):821-829. PubMed ID: 38549422
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
[TBL] [Abstract][Full Text] [Related]
12. Impact of carbapenem versus non-carbapenem treatment on the rates of superinfection: A meta-analysis of randomized controlled trials.
Eljaaly K; Enani MA; Al-Tawfiq JA
J Infect Chemother; 2018 Nov; 24(11):915-920. PubMed ID: 30197092
[TBL] [Abstract][Full Text] [Related]
13. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study.
Rando E; Salvati F; Sangiorgi F; Catania F; Leone E; Oliva A; Di Gennaro F; Fiori B; Cancelli F; Figliomeni S; Bobbio F; Sacco F; Bavaro DF; Diella L; Belati A; Saracino A; Mastroianni CM; Fantoni M; Murri R
J Antimicrob Chemother; 2024 Feb; 79(2):453-461. PubMed ID: 38169441
[TBL] [Abstract][Full Text] [Related]
14. Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae.
Zohar I; Schwartz O; Yossepowitch O; David SSB; Maor Y
J Antimicrob Chemother; 2020 Feb; 75(2):458-465. PubMed ID: 31691817
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
Lu B; Wong M; Ha D; Bounthavong M; Banaei N; Deresinski S; Diep C
J Antimicrob Chemother; 2023 Apr; 78(4):1009-1014. PubMed ID: 36879495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients.
Ko JH; Kim SH; Kang CI; Cho SY; Lee NY; Chung DR; Peck KR; Song JH
J Korean Med Sci; 2019 Jan; 34(2):e17. PubMed ID: 30636947
[TBL] [Abstract][Full Text] [Related]
17. Meropenem versus piperacillin-tazobactam for the treatment of pancreatic necrosis.
Racketa S; Gandhi K; Lambie M
Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116209. PubMed ID: 38458097
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
20. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
